| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.51▲ | 3.46▲ | 3.43▲ | 3.34▲ | 3.65▼ |
| MA10 | 3.46▲ | 3.40▲ | 3.34▲ | 3.51▲ | 3.51▼ |
| MA20 | 3.43▲ | 3.30▲ | 3.21▲ | 3.64▼ | 2.67▲ |
| MA50 | 3.32▲ | 3.22▲ | 3.37▲ | 3.44▲ | 3.25▲ |
| MA100 | 3.20▲ | 3.42▲ | 3.51▲ | 2.64▲ | N/A |
| MA200 | 3.23▲ | 3.53▼ | 3.71▼ | 3.02▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.006▲ | 0.028▲ | 0.054▲ | -0.064▼ | 0.213▲ |
| RSI | 67.146▲ | 72.180▲ | 64.843▲ | 49.122▼ | 52.670▲ |
| STOCH | 78.567 | 94.627▲ | 89.516▲ | 27.150 | 46.140 |
| WILL %R | -14.286▲ | -7.246▲ | -5.882▲ | -50.401 | -56.423 |
| CCI | 112.168▲ | 131.667▲ | 158.353▲ | -37.647 | 22.368 |
|
Friday, August 08, 2025 04:09 AM
Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased expenses and competitive challenges.
|
|
Thursday, August 07, 2025 05:38 PM
Skye Bioscience nears Phase IIa data for nimacimab, targeting obesity treatment gaps with robust preclinical insights.
|
|
Monday, July 28, 2025 07:58 PM
Monday, CHPT closed at $9.91, down 18.85%, and edged up 0.40% in after-hours trading to $9.95 on the NYSE. The views and opinions expressed herein are the views and opinions of the author and do ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 3.31 | 3.56 | 3.2153 | 3.51 | 395,911 |
| 14/08/25 | 3.11 | 3.28 | 3.11 | 3.27 | 231,194 |
| 13/08/25 | 3.26 | 3.27 | 2.96 | 3.14 | 604,640 |
| 12/08/25 | 3.50 | 3.56 | 3.2124 | 3.25 | 405,820 |
| 11/08/25 | 3.50 | 3.7099 | 3.36 | 3.51 | 281,878 |
| 08/08/25 | 3.50 | 3.52 | 3.35 | 3.52 | 250,174 |
| 07/08/25 | 3.96 | 4.0689 | 3.54 | 3.55 | 443,687 |
| 06/08/25 | 3.84 | 4.065 | 3.58 | 3.89 | 437,399 |
| 05/08/25 | 3.70 | 3.82 | 3.66 | 3.79 | 214,634 |
| 04/08/25 | 3.45 | 3.705 | 3.4175 | 3.63 | 276,792 |
|
|
||||
|
|
||||
|
|